Skip to main content
OpenTrials
Active, not recruiting

NCT Number: NCT07778329

Psychosocial Intervention for Behavioral Symptoms in Hospitalized Patients With Dementia or Delirium

Behavioral and psychological symptoms are common among older adults hospitalized with dementia or delirium and may include agitation, wandering, delusions, hallucinations, aggression, oppositional behavior, and sleep disturbances. These symptoms can increase the risk of falls, prolonged hospitalization, functional decline, institutionalization, and caregiver burden. Pharmacological treatment and physical restraint may be ineffective or may worsen clinical outcomes, while evidence on non-pharmacological interventions in acute hospital settings remains limited.

The ESSECOA study is a single-center, randomized, controlled, open-label trial conducted in the Geriatric Unit of the Azienda Ospedaliero-Universitaria di Modena. It evaluates whether adding a structured psychosocial intervention to standard pharmacological management is more effective than standard pharmacological management alone in reducing behavioral disturbances in hospitalized patients aged over 65 years with dementia and/or delirium.

Eligible participants are randomized to one of two parallel groups. The control group receives pharmacological management according to clinical guidelines and best practice. The intervention group receives the same pharmacological management plus sensory and general stimulation sessions three times per week, lasting approximately 40 minutes each. The intervention is individualized according to the patient's history, preferences, target symptoms, and residual abilities. Caregivers are involved during the stimulation sessions and receive two structured educational interventions, one during hospitalization and one before discharge, aimed at improving communication and management strategies that can also be used at home.

The primary objective is to compare the change in behavioral symptoms between groups using the Neuropsychiatric Inventory (NPI). Secondary objectives are to identify which behavioral symptoms respond best to the non-pharmacological approach, particularly in relation to caregiver education. Additional assessments include delirium, cognitive and functional status, depression, comorbidity, antipsychotic medication use, length of hospital stay, discharge destination, healthcare use, mortality, caregiver burden, perceived competence, and perceived needs.

Active, not recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

65 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Ospedale Civile di Baggiovara

Modena, Emilia-Romagna, 41124, Italy

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age older than 65 years.
  • Diagnosis of dementia and/or delirium.
  • Availability of a caregiver who also assists the participant at home and is willing to participate in the caregiver education program.
  • Presence of behavioral disturbances, defined as a Neuropsychiatric Inventory (NPI) total score of 24 or higher, or a score of 12 in at least one NPI symptom domain.
  • No clinical condition at hospital admission that would prevent delivery of the non-pharmacological intervention, including isolation for SARS-CoV-2 infection or another condition requiring isolation, deep sedation, coma, or severe respiratory failure.
  • Written informed consent provided by the participant, when capable of providing consent, or by the participant's legal guardian or legally authorized representative.
  • Written informed consent provided by the caregiver.

Exclusion criteria

  • Age younger than 65 years.
  • No diagnosis of dementia or delirium.
  • No available caregiver, or caregiver unwilling or unable to participate in the education program.
  • NPI total score lower than 24 and no individual NPI symptom domain score of 12.
  • Clinical condition present at admission or developing during hospitalization that prevents delivery of the non-pharmacological intervention, including isolation for SARS-CoV-2 infection or another condition requiring isolation, deep sedation, coma, or severe respiratory failure.
  • Informed consent not obtained from the participant, when capable of providing consent, or from the participant's legal guardian or legally authorized representative.
  • Informed consent not obtained from the caregiver.

Treatment and study plan

Sensory and General Stimulation With Caregiver Education

Behavioral

Participants receive individualized sensory and general stimulation administered by trained geriatric unit staff three times per week during hospitalization, with each session lasting approximately 40 minutes. Activities are tailored to the participant's personal history, preferences, target behavioral symptoms, and residual abilities. They may include multisensory stimulation in a Snoezelen environment and simple meaningful activities involving the senses. Caregivers participate in the stimulation sessions and receive two structured educational sessions, one during hospitalization and one before discharge, focused on communication and individualized strategies for managing behavioral symptoms at home.

Other names: Psychosocial Intervention, Snoezelen-Based Intervention

Standard Pharmacological Management

Other

Behavioral symptoms are managed according to applicable clinical guidelines and, where specific guidelines are unavailable, according to best clinical practice. Treatment is individualized by the treating physician according to the participant's target symptoms, clinical condition, and comorbidities. The protocol does not mandate a specific study drug, dose, or fixed treatment regimen. Caregivers receive routine information regarding the participant's clinical condition and plan of care.

Primary outcomes

  1. Change From Baseline in Neuropsychiatric Inventory Total Score at Hospital Discharge

    Time frame: Baseline and hospital discharge, up to 45 days

    The Neuropsychiatric Inventory (NPI) assesses behavioral and psychological symptoms in participants with dementia and/or delirium. The primary outcome is the change in total NPI score from baseline to the pre-discharge assessment. The mean change will be compared between the two study arms. A between-group difference of at least 10 points is considered clinically relevant. Higher scores indicate more severe behavioral symptoms.

Secondary outcomes

  1. Change From Baseline in Individual Neuropsychiatric Inventory Domain Scores at Hospital Discharge

    Time frame: Baseline and hospital discharge, up to 45 days

    Changes in individual Neuropsychiatric Inventory (NPI) symptom domain scores from baseline to the pre-discharge assessment will be compared between the two study arms to determine which behavioral symptoms show greater improvement with the addition of the psychosocial intervention. Higher scores indicate greater symptom severity.

Sponsors and collaborators

Lead sponsor

Azienda Ospedaliero-Universitaria di Modena

Other

Registry information

Official study title

Efficacy of a Psychosocial Intervention (Sensory and General Stimulation and Caregiver Education) in Patients With Behavioral Disturbances Associated With Dementia or Delirium Hospitalized in an Acute Care Hospital: The ESSECOA Longitudinal Study

Acronym: ESSECOA

Important dates

Study start
2021
Primary completion
2026
Study completion
2026
First posted
Aug 21, 2026
Registry last updated
Aug 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.